{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:33:43Z","timestamp":1778535223716,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001922","name":"DH | NIHR | Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["11\/100\/76"],"award-info":[{"award-number":["11\/100\/76"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Versus Arthritis Experimental Arthritis Treatment Centre"},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["TRF-2018-11-ST2-002"],"award-info":[{"award-number":["TRF-2018-11-ST2-002"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Versus Arthritis clinical lectureship (grant number: 21890)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5\u201320% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; <jats:italic>n<\/jats:italic>\u2009=\u2009164), patients with low\/absent synovial B\u2009cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response\/nonresponse remain to be established. Here, in-depth histological\/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal\/fibroblast signature in patients refractory to all medications. Post-treatment changes in synovial gene expression and cell infiltration highlighted divergent effects of rituximab and tocilizumab relating to differing response\/nonresponse mechanisms. Using ten-by-tenfold nested cross-validation, we developed machine learning algorithms predictive of response to rituximab (area under the curve (AUC)\u2009=\u20090.74), tocilizumab (AUC\u2009=\u20090.68) and, notably, multidrug resistance (AUC\u2009=\u20090.69). This study supports the notion that disease endotypes, driven by diverse molecular pathology pathways in the diseased tissue, determine diverse clinical and treatment\u2013response phenotypes. It also highlights the importance of integration of molecular pathology signatures into clinical algorithms to optimize the future use of existing medications and inform the development of new drugs for refractory patients.<\/jats:p>","DOI":"10.1038\/s41591-022-01789-0","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T16:05:03Z","timestamp":1652976303000},"page":"1256-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":263,"title":["Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-7521","authenticated-orcid":false,"given":"Felice","family":"Rivellese","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-3005","authenticated-orcid":false,"given":"Anna E. A.","family":"Surace","sequence":"additional","affiliation":[]},{"given":"Katriona","family":"Goldmann","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7525-1558","authenticated-orcid":false,"given":"Elisabetta","family":"Sciacca","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-0849","authenticated-orcid":false,"given":"Cankut","family":"\u00c7ubuk","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Giorli","sequence":"additional","affiliation":[]},{"given":"Christopher R.","family":"John","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-4014","authenticated-orcid":false,"given":"Alessandra","family":"Nerviani","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-3999","authenticated-orcid":false,"given":"Liliane","family":"Fossati-Jimack","sequence":"additional","affiliation":[]},{"given":"Georgina","family":"Thorborn","sequence":"additional","affiliation":[]},{"given":"Manzoor","family":"Ahmed","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6830-0614","authenticated-orcid":false,"given":"Edoardo","family":"Prediletto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-4282","authenticated-orcid":false,"given":"Sarah E.","family":"Church","sequence":"additional","affiliation":[]},{"given":"Briana M.","family":"Hudson","sequence":"additional","affiliation":[]},{"given":"Sarah E.","family":"Warren","sequence":"additional","affiliation":[]},{"given":"Paul M.","family":"McKeigue","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1280-9133","authenticated-orcid":false,"given":"Frances","family":"Humby","sequence":"additional","affiliation":[]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9097-7381","authenticated-orcid":false,"given":"Michael R.","family":"Barnes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-5345","authenticated-orcid":false,"given":"Myles J.","family":"Lewis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-5051","authenticated-orcid":false,"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[]},{"name":"the R4RA collaborative group","sequence":"additional","affiliation":[]},{"given":"Felice","family":"Rivellese","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Giorli","sequence":"additional","affiliation":[]},{"given":"Alessandra","family":"Nerviani","sequence":"additional","affiliation":[]},{"given":"Liliane","family":"Fossati-Jimack","sequence":"additional","affiliation":[]},{"given":"Georgina","family":"Thorborn","sequence":"additional","affiliation":[]},{"given":"Frances","family":"Humby","sequence":"additional","affiliation":[]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[]},{"given":"Myles J.","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[]},{"given":"Maya H.","family":"Buch","sequence":"additional","affiliation":[]},{"given":"Hasan","family":"Rizvi","sequence":"additional","affiliation":[]},{"given":"Arti","family":"Mahto","sequence":"additional","affiliation":[]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Lauwerys","sequence":"additional","affiliation":[]},{"given":"Nora","family":"Ng","sequence":"additional","affiliation":[]},{"given":"Pauline","family":"Ho","sequence":"additional","affiliation":[]},{"given":"Vasco C.","family":"Rom\u00e3o","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Eurico Cabral","family":"da Fonseca","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[]},{"given":"Stephen","family":"Kelly","sequence":"additional","affiliation":[]},{"given":"Pier Paolo","family":"Sainaghi","sequence":"additional","affiliation":[]},{"given":"Nagui","family":"Gendi","sequence":"additional","affiliation":[]},{"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[]},{"given":"Piero","family":"Reynolds","sequence":"additional","affiliation":[]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[]},{"given":"Julio","family":"Ramirez","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Celis","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Moots","sequence":"additional","affiliation":[]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[]},{"given":"Chris J.","family":"Edwards","sequence":"additional","affiliation":[]},{"given":"John","family":"Isaacs","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Sasieni","sequence":"additional","affiliation":[]},{"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[]},{"given":"Charlotte","family":"Thompson","sequence":"additional","affiliation":[]},{"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[]},{"given":"Mattia","family":"Bellan","sequence":"additional","affiliation":[]},{"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[]},{"given":"Christopher","family":"Holroyd","sequence":"additional","affiliation":[]},{"given":"Arthur","family":"Pratt","sequence":"additional","affiliation":[]},{"given":"Laura","family":"White","sequence":"additional","affiliation":[]},{"given":"Louise","family":"Warren","sequence":"additional","affiliation":[]},{"given":"Joanna","family":"Peel","sequence":"additional","affiliation":[]},{"given":"Rebecca","family":"Hands","sequence":"additional","affiliation":[]},{"given":"Gaye","family":"Hadfield","sequence":"additional","affiliation":[]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"1789_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Prim. 4, 18001 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1789_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","volume":"77","author":"MH Buch","year":"2018","unstructured":"Buch, M. H. Defining refractory rheumatoid arthritis. Ann. Rheum. Dis. 77, 966\u2013969 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1789_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.clbc.2014.10.006","volume":"15","author":"P Kawalec","year":"2015","unstructured":"Kawalec, P., \u0141opuch, S. & Mikrut, A. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis. Clin. Breast Cancer 15, 90\u2013100 (2015).","journal-title":"Clin. Breast Cancer"},{"key":"1789_CR5","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","volume":"16","author":"C Pitzalis","year":"2020","unstructured":"Pitzalis, C., Choy, E. H. S. & Buch, M. H. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat. Rev. Rheumatol. 16, 590\u2013599 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1789_CR6","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","volume":"28","author":"MJ Lewis","year":"2019","unstructured":"Lewis, M. J. et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 28, 2455\u20132470 (2019).","journal-title":"Cell Rep."},{"key":"1789_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","volume":"78","author":"F Humby","year":"2019","unstructured":"Humby, F. et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann. Rheum. Dis. 78, 761\u2013772 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR8","doi-asserted-by":"publisher","first-page":"102738","DOI":"10.1016\/j.autrev.2020.102738","volume":"20","author":"R Giacomelli","year":"2021","unstructured":"Giacomelli, R. et al. The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and experts\u2019 consensus. Autoimmun. Rev. 20, 102738 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1789_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby, F. et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397, 305\u2013317 (2021).","journal-title":"Lancet"},{"key":"1789_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"1789_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58766-1","volume":"10","author":"CR John","year":"2020","unstructured":"John, C. R. et al. M3C: Monte Carlo reference-based consensus clustering. Sci. Rep. 10, 1816 (2020).","journal-title":"Sci. Rep."},{"key":"1789_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195\u2013204 (2014).","journal-title":"Nat. Immunol."},{"key":"1789_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02659-x","volume":"9","author":"W Stephenson","year":"2018","unstructured":"Stephenson, W. et al. Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. Nat. Commun. 9, 791 (2018).","journal-title":"Nat. Commun."},{"key":"1789_CR14","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928\u2013942 (2019).","journal-title":"Nat. Immunol."},{"key":"1789_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","volume":"582","author":"K Wei","year":"2020","unstructured":"Wei, K. et al. Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582, 259\u2013264 (2020).","journal-title":"Nature"},{"key":"1789_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","volume":"570","author":"AP Croft","year":"2019","unstructured":"Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246\u2013251 (2019).","journal-title":"Nature"},{"key":"1789_CR17","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.4049\/jimmunol.1101717","volume":"187","author":"K Crozat","year":"2011","unstructured":"Crozat, K. et al. Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8\u03b1+ type. J. Immunol. 187, 4411\u20134415 (2011).","journal-title":"J. Immunol."},{"key":"1789_CR18","doi-asserted-by":"publisher","first-page":"18537","DOI":"10.1074\/jbc.M109.012807","volume":"284","author":"SA Graham","year":"2009","unstructured":"Graham, S. A. et al. Prolectin, a glycan-binding receptor on dividing B cells in germinal centers. J. Biol. Chem. 284, 18537\u201318544 (2009).","journal-title":"J. Biol. Chem."},{"key":"1789_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41584-020-0409-1","volume":"16","author":"AM Curran","year":"2020","unstructured":"Curran, A. M., Naik, P., Giles, J. T. & Darrah, E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat. Rev. Rheumatol. 16, 301\u2013315 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1789_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.53.1.39","volume":"53","author":"G Yanni","year":"1994","unstructured":"Yanni, G., Whelan, A., Feighery, C. & Bresnihan, B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann. Rheum. Dis. 53, 39\u201344 (1994).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR21","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3899\/jrheum.090348","volume":"36","author":"B Bresnihan","year":"2009","unstructured":"Bresnihan, B. et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J. Rheumatol. 36, 1800\u20131802 (2009).","journal-title":"J. Rheumatol."},{"key":"1789_CR22","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1002\/art.22967","volume":"56","author":"YK Teng","year":"2007","unstructured":"Teng, Y. K. et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum. 56, 3909\u20133918 (2007).","journal-title":"Arthritis Rheum."},{"key":"1789_CR23","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1136\/annrheumdis-2011-201115","volume":"71","author":"VE Hogan","year":"2012","unstructured":"Hogan, V. E. et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann. Rheum. Dis. 71, 1888\u20131894 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy, E. H. et al. Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335\u2013345 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1789_CR25","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3819","volume":"14","author":"HG Raterman","year":"2012","unstructured":"Raterman, H. G. et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res. Ther. 14, R95 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1789_CR26","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1002\/art.27702","volume":"62","author":"RM Thurlings","year":"2010","unstructured":"Thurlings, R. M. et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 62, 3607\u20133614 (2010).","journal-title":"Arthritis Rheum."},{"key":"1789_CR27","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"G Lliso-Ribera","year":"2019","unstructured":"Lliso-Ribera, G. et al. Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann. Rheum. Dis. 78, 1642\u20131652 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3389\/fimmu.2020.00845","volume":"11","author":"A Nerviani","year":"2020","unstructured":"Nerviani, A. et al. A pauci-immune synovial pathotype predicts inadequate response to TNF\u03b1-blockade in rheumatoid arthritis patients. Front. Immunol. 11, 845 (2020).","journal-title":"Front. Immunol."},{"key":"1789_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02892-y","volume":"9","author":"F Mizoguchi","year":"2018","unstructured":"Mizoguchi, F. et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat. Commun. 9, 789 (2018).","journal-title":"Nat. Commun."},{"key":"1789_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07987-0","volume":"10","author":"N Ferrari","year":"2019","unstructured":"Ferrari, N. et al. Dickkopf-3 links HSF1 and YAP\/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat. Commun. 10, 130 (2019).","journal-title":"Nat. Commun."},{"key":"1789_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/imr.12986","volume":"302","author":"LJ Marsh","year":"2021","unstructured":"Marsh, L. J., Kemble, S., Reis Nisa, P., Singh, R. & Croft, A. P. Fibroblast pathology in inflammatory joint disease. Immunol. Rev. 302, 163\u2013183 (2021).","journal-title":"Immunol. Rev."},{"key":"1789_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/rheumatology\/kei209","volume":"45","author":"T Iwamoto","year":"2006","unstructured":"Iwamoto, T. et al. Monocyte chemoattractant protein-4 (MCP-4)\/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. Rheumatology (Oxford) 45, 421\u2013424 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"1789_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-017-1244-x","volume":"19","author":"S Salomon","year":"2017","unstructured":"Salomon, S. et al. Th17 and CD24(hi)CD27(+) regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis. Arthritis Res. Ther. 19, 33 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"1789_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. 79, 685\u2013699 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR35","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/art.23290","volume":"58","author":"B Vandooren","year":"2008","unstructured":"Vandooren, B., Cantaert, T., Noordenbos, T., Tak, P. P. & Baeten, D. The abundant synovial expression of the RANK\/RANKL\/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 58, 718\u2013729 (2008).","journal-title":"Arthritis Rheum."},{"key":"1789_CR36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/ard.2007.074229","volume":"67","author":"A Kavanaugh","year":"2008","unstructured":"Kavanaugh, A. et al. Assessment of rituximab\u2019s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann. Rheum. Dis. 67, 402\u2013408 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR37","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"TH Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe, T. H. et al. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology (Oxford) 58, 1075\u20131085 (2019).","journal-title":"Rheumatology (Oxford)"},{"key":"1789_CR38","doi-asserted-by":"publisher","first-page":"155650","DOI":"10.1016\/j.cyto.2021.155650","volume":"146","author":"DG Hill","year":"2021","unstructured":"Hill, D. G., Ward, A., Nicholson, L. B. & Jones, G. W. Emerging roles for IL-6 family cytokines as positive and negative regulators of ectopic lymphoid structures. Cytokine 146, 155650 (2021).","journal-title":"Cytokine"},{"key":"1789_CR39","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1093\/rheumatology\/keaa529","volume":"59","author":"B Nouri","year":"2020","unstructured":"Nouri, B., Nair, N. & Barton, A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology (Oxford) 59, 3603\u20133610 (2020).","journal-title":"Rheumatology (Oxford)"},{"key":"1789_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs, J. D. et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. 72, 329\u2013336 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR41","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0962280217738807","volume":"28","author":"P McKeigue","year":"2019","unstructured":"McKeigue, P. Sample size requirements for learning to classify with high-dimensional biomarker panels. Stat. Methods Med. Res. 28, 904\u2013910 (2019).","journal-title":"Stat. Methods Med. Res."},{"key":"1789_CR42","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/annrheumdis-2013-204603","volume":"74","author":"S Kelly","year":"2015","unstructured":"Kelly, S. et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann. Rheum. Dis. 74, 611\u2013617 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"1789_CR43","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/rheumatology\/keu163","volume":"53","author":"S Bugatti","year":"2014","unstructured":"Bugatti, S. et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology (Oxford) 53, 1886\u20131895 (2014).","journal-title":"Rheumatology (Oxford)"},{"key":"1789_CR44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/art.41184","volume":"72","author":"F Rivellese","year":"2020","unstructured":"Rivellese, F. et al. B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure. Arthritis Rheumatol. 72, 714\u2013725 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"1789_CR45","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2559.2006.02508.x","volume":"49","author":"V Krenn","year":"2006","unstructured":"Krenn, V. et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, 358\u2013364 (2006).","journal-title":"Histopathology"},{"key":"1789_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"1789_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1789_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-2-r29","volume":"15","author":"CW Law","year":"2014","unstructured":"Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).","journal-title":"Genome Biol."},{"key":"1789_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"1789_CR50","doi-asserted-by":"publisher","first-page":"bbaa163","DOI":"10.1093\/bib\/bbaa163","volume":"22","author":"A Bhattacharya","year":"2021","unstructured":"Bhattacharya, A. et al. An approach for normalization and quality control for NanoString RNA expression data. Brief. Bioinform. 22, bbaa163 (2021).","journal-title":"Brief. Bioinform."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01789-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01789-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01789-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:05:51Z","timestamp":1655478351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01789-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01789-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"28 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.E.C., B.M.H. and S.E.W. are employees and stockholders of NanoString Technologies, Inc. C.P. and M.J.L. are inventors on a patent application (no. GB 2100821.4), submitted by Queen Mary University of London, that covers methods used to select treatments in RA. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}